Latest numbers on COVID-19 in the UK – 4th June 2021

Not much good news this week

1. Cases
2. Variants
3. Hospitalisations & Deaths
4. Vaccination
5. Schools

With many thanks to Bob for his help in collating the data
Cases
Number of new UK confirmed COVID-19 cases by reported date (people who have had a positive test)

Data from https://coronavirus.data.gov.uk
Number of new UK confirmed COVID-19 cases by reported date
(people who have had a positive test)

Data from https://coronavirus.data.gov.uk
Number of tests performed each day by LFD or PCR type in England (to 2\textsuperscript{nd} June)

Data from https://coronavirus.data.gov.uk
Number of cases per 100,000 people per week for UK nations by date reported to 3rd June

Data from https://coronavirus.data.gov.uk
Number of cases per 100,000 people per week for UK nations w/e 3 June ● compared to w/e 27 May ○ and 1 Sept 2020 ◆

Data from https://coronavirus.data.gov.uk
Cases per 100K per Week for English Regions
Comparison of week ending May 29 ● to prior week ● to week ending Sep 1 ●

Data from https://coronavirus.data.gov.uk/
Thanks to Bob Hawkins for the chart
Cases per 100K Per Week for All Scottish Local Authorities
Comparison of week ending May 29 to prior week

Local Authorities Ranked by Cases

Data from https://coronavirus.data.gov.uk/
Thanks to Bob Hawkins for the chart
Variants
Spread of Delta (B.1.617.2) from the Wellcome Sanger Institute

https://covid19.sanger.ac.uk/lineages/downloads
Spread of Delta (B.1.617.2) from the Wellcome Sanger Institute

https://covid19.sanger.ac.uk/lineages/downloads
Geographical spread of Delta (B.1.617.2) from the Wellcome Sanger Institute

https://covid19.sanger.ac.uk/lineages/raw

17 April

1 May

15 May
Two epidemics have been happening at once

https://covid19.sanger.ac.uk/lineages/downloads

Data from https://covid19.sanger.ac.uk/downloads.
Number of sequenced Delta variant tests from COG UK in England to 22 May

http://sars2.cvr.gla.ac.uk/cog-uk/
We now know a lot about the Delta variant

<table>
<thead>
<tr>
<th>Indicator</th>
<th>RAG*</th>
<th>Confidence</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissibility</td>
<td>HIGH</td>
<td></td>
<td><strong>Transmissibility appears greater than wild type (first wave) SARS-CoV-2</strong></td>
</tr>
<tr>
<td>between humans</td>
<td></td>
<td></td>
<td>Delta continues to demonstrate a substantially increased growth rate compared to Alpha, across multiple analyses. Delta cases are rising whilst Alpha cases are declining. Secondary attack rates, including household secondary attack rates, are higher for Delta, but these are not yet corrected for vaccination status. There is in vitro evidence suggestive of increased replication in biological systems that model human airway. It is highly likely that Delta is significantly more transmissible than Alpha.</td>
</tr>
</tbody>
</table>

Public Health England
We now know a lot about the Delta variant

### 3 June 2021 Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>RAG*</th>
<th>Confidence</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissibility between</td>
<td>HIGH</td>
<td></td>
<td>Transmissibility appears greater than wild type (first wave) SARS-CoV-2. Delta continues to demonstrate a substantially increased growth rate compared to Alpha, across multiple analyses. Delta cases are rising whilst Alpha cases are declining. Secondary attack rates, including household secondary attack rates, are higher for Delta, but these are not yet corrected for vaccination status. There is in vitro evidence suggestive of increased replication in biological systems that model human airway. <em>It is highly likely that Delta is significantly more transmissible than Alpha.</em></td>
</tr>
<tr>
<td>humans</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection severity</td>
<td>LOW</td>
<td></td>
<td>Increased severity (hospitalisation risk) when compared to Alpha. Early evidence from England and Scotland suggests there may be an increased risk of hospitalisation compared to contemporaneous Alpha cases. A large number of cases are still within the follow up period. In some areas, hospital admissions show early signs of increasing, but the national trend is not clear.</td>
</tr>
</tbody>
</table>
We now know a lot about the Delta variant

<table>
<thead>
<tr>
<th>Indicator</th>
<th>RAG*</th>
<th>Confidence</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissibility between humans</td>
<td>HIGH</td>
<td></td>
<td>Transmissibility appears greater than wild type (first wave) SARS-CoV-2. Delta continues to demonstrate a substantially increased growth rate compared to Alpha, across multiple analyses. Delta cases are rising whilst Alpha cases are declining. Secondary attack rates, including household secondary attack rates, are higher for Delta, but these are not yet corrected for vaccination status. There is in vitro evidence suggestive of increased replication in biological systems that model human airway. It is highly likely that Delta is significantly more transmissible than Alpha.</td>
</tr>
<tr>
<td>Infection severity</td>
<td>LOW</td>
<td></td>
<td>Increased severity (hospitalisation risk) when compared to Alpha. Early evidence from England and Scotland suggests there may be an increased risk of hospitalisation compared to contemporaneous Alpha cases. A large number of cases are still within the follow up period. In some areas, hospital admissions show early signs of increasing, but the national trend is not clear.</td>
</tr>
<tr>
<td>Vaccines</td>
<td>HIGH</td>
<td></td>
<td>Epidemiological and laboratory evidence of reduced vaccine effectiveness. There are now analyses from England and Scotland supporting a reduction in vaccine effectiveness for Delta compared to Alpha. This is more pronounced after one dose (absolute reduction in vaccine effectiveness against symptomatic infection of approximately 15-20% after 1 dose). Iterated analysis continues to show vaccine effectiveness against Delta is higher after 2 doses but that there is a reduction for Delta compared to Alpha. There is a high level of uncertainty around the magnitude of the change in vaccine effectiveness after 2 doses of Oxford-AstraZeneca vaccine. Although this is observational data subject to some biases, it holds true across several analytic approaches and the same effect is seen in both English and Scottish data. It is strongly supported by pseudovirus and live virus neutralisation data from multiple laboratories. There are no data on whether prevention of transmission is affected and insufficient data to assess vaccine effectiveness against severe disease. The acquisition of an additional mutation which may be antigenically significant in a small number of cases is noted.</td>
</tr>
</tbody>
</table>
We now know a lot about the Delta variant

### 3 June 2021 Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2) Public Health England

<table>
<thead>
<tr>
<th>Indicator</th>
<th>RAG*</th>
<th>Confidence</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissibility between</td>
<td>HIGH</td>
<td></td>
<td>Transmissibility appears greater than wild type (first wave) SARS-CoV-2</td>
</tr>
<tr>
<td>humans</td>
<td></td>
<td></td>
<td>Delta continues to demonstrate a substantially increased growth rate compared to Alpha,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>across multiple analyses. Delta cases are rising whilst Alpha cases are declining.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary attack rates, including household secondary attack rates, are higher for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Delta, but these are not yet corrected for vaccination status. There is in vitro</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>evidence suggestive of increased replication in biological systems that model</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>human airway. It is highly likely that Delta is significantly more transmissible</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>than Alpha.</td>
</tr>
<tr>
<td>Infection severity</td>
<td>LOW</td>
<td></td>
<td>Increased severity (hospitalisation risk) when compared to Alpha</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early evidence from England and Scotland suggests there may be an increased risk of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hospitalisation compared to contemporaneous Alpha cases. A large number of cases are</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>still within the follow up period. In some areas, hospital admissions show early signs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>of increasing, but the national trend is not clear.</td>
</tr>
<tr>
<td>Vaccines</td>
<td>HIGH</td>
<td></td>
<td>Epidemiological and laboratory evidence of reduced vaccine effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>There are now analyses from England and Scotland supporting a reduction in vaccine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>effectiveness for Delta compared to Alpha. This is more pronounced after one dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(absolute reduction in vaccine effectiveness against symptomatic infection of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>approximately 15-20% after 1 dose). Iterated analysis continues to show vaccine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>effectiveness against Delta is higher after 2 doses but that there is a reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>for Delta compared to Alpha. There is a high level of uncertainty around the</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>magnitude of the change in vaccine effectiveness after 2 doses of Oxford-AstraZeneca</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>vaccine.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Although this is observational data subject to some biases, it holds true across</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>several analytic approaches and the same effect is seen in both English and Scottish</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>data. It is strongly supported by pseudovirus and live virus neutralisation data from</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>multiple laboratories. There are no data on whether prevention of transmission is</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>affected and insufficient data to assess vaccine effectiveness against severe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>disease. The acquisition of an additional mutation which may be antigenically</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>significant in a small number of cases is noted.</td>
</tr>
</tbody>
</table>
We now know a lot about the Delta variant

Pfizer:
“These data, together with epidemiological data of B.1.617.2 growth, raise the possibility that this VOC [Delta] presents a dual challenge of reduced vaccine efficacy akin to the B.1.351 VOC [Beta] and increased transmissibility beyond the B.1.1.7 VOC [Alpha].”

https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901290-3
We now know a lot about the Delta variant

### 3 June 2021 Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>RAG*</th>
<th>Confidence</th>
<th>Assessment and rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmissibility between humans</td>
<td>HIGH</td>
<td></td>
<td>Transmissibility appears greater than wild type (first wave) SARS-CoV-2. Delta continues to demonstrate a substantially increased growth rate compared to Alpha, across multiple analyses. Delta cases are rising whilst Alpha cases are declining. Secondary attack rates, including household secondary attack rates, are higher for Delta, but these are not yet corrected for vaccination status. There is in vitro evidence suggestive of increased replication in biological systems that model human airway. <strong>It is highly likely that Delta is significantly more transmissible than Alpha.</strong></td>
</tr>
<tr>
<td>Infection severity</td>
<td>LOW</td>
<td></td>
<td>Increased severity (hospitalisation risk) when compared to Alpha. Early evidence from England and Scotland suggests there may be an increased risk of hospitalisation compared to contemporaneous Alpha cases. A large number of cases are still within the follow up period. In some areas, hospital admissions show early signs of increasing, but the national trend is not clear.</td>
</tr>
<tr>
<td>Vaccines</td>
<td>HIGH</td>
<td></td>
<td>Epidemiological and laboratory evidence of reduced vaccine effectiveness. There are now analyses from England and Scotland supporting a reduction in vaccine effectiveness for Delta compared to Alpha. This is more pronounced after one dose (absolute reduction in vaccine effectiveness against symptomatic infection of approximately 15-20% after 1 dose). Iterated analysis continues to show vaccine effectiveness against Delta is higher after 2 doses but that there is a reduction for Delta compared to Alpha. There is a high level of uncertainty around the magnitude of the change in vaccine effectiveness after 2 doses of Oxford-AstraZeneca vaccine. Although this is observational data subject to some biases, it holds true across several analytic approaches and the same effect is seen in both English and Scottish data. <strong>It is strongly supported by pseudovirus and live virus neutralisation data from multiple laboratories. There are no data on whether prevention of transmission is affected and insufficient data to assess vaccine effectiveness against severe disease. The acquisition of an additional mutation which may be antigenically significant in a small number of cases is noted.</strong></td>
</tr>
</tbody>
</table>

---

**Pfizer:**

“In the case of single-dose recipients, our data show that NAbTs are **significantly lower** against B.1.617.2 and B.1.351 VOCs relative to B.1.1.7”

[https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901290-3](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901290-3)
We now know a lot about the Delta variant

Pfizer:
“we note that both increased age and time since the second dose of BNT162b2 significantly correlate with decreased NAb activity against B.1.617.2 and B.1.351—both of which are also characteristic of the population in the UK at highest risk of severe COVID-19 (ie, older and vaccinated earlier)”

https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901290-3
Hospitalisations and Deaths
Number of people in hospital per million people – UK nations to 2 June

Data from https://coronavirus.data.gov.uk.
Number of new admissions to hospital in England to 1st June

Data from https://coronavirus.data.gov.uk.
Number of new admissions to hospital in Scotland to 26 May

Number of new UK deaths from COVID-19 per week to week ending 21st May 2021

Data from:
England and Wales: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/latest
Northern Ireland: www.nisra.gov.uk/publications/weekly-deaths

115 w/e 21st May, 2021
Vaccination data
Number of 1\textsuperscript{st} and 2\textsuperscript{nd} doses given by day in the UK to 2\textsuperscript{nd} June

3.5 million people received a jab in the week to 2\textsuperscript{nd} June
4.1 million people received a jab in the week to 26\textsuperscript{th} May

Data from https://coronavirus.data.gov.uk/
Thanks to Bob Hawkins for the chart
Percentage of overall population not (0 doses), partially (1 dose) and fully (2 doses) vaccinated by home nation

Data from https://coronavirus.data.gov.uk.
First and Second Dose Coverage by Age for England to 30th May

Data from https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations
Thanks to Bob Hawkins for the chart
First dose coverage for over 50s by ethnicity for England to 30th May


Thanks to Bob Hawkins for the chart
Schools
Age distribution of cases – Public Health England to 30th May

Percentage of population testing positive by age in England (to 29th May) (ONS infection survey)

Figure 3: The percentage of people testing positive has increased in those aged 35 years and over and in school Year 7 to school Year 11 in the week ending 29 May 2021.

Estimated percentage of the population testing positive for coronavirus (COVID-19) on nose and throat swabs, daily, by age group since 18 April 2021, England.

Chart from https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/latest
School outbreaks – Public Health England to 30th May

Number of COVID-19 confirmed clusters or outbreaks by type of educational setting, England

Events and activities reported by people testing positive, prior to symptom onset in week 21, England
(Data source: NHS Test and Trace)

- Attending childcare educational setting
- Shopping
- Other (combined)
- Exercising
- Eating Out
- Other occupational sector
- Visiting friends or relatives
- Living alone or with family
- Other
- Teaching and education
- Travel and commuting
- Manufacturing or construction
- Retail sector
- Healthcare
- Warehouse or distribution
- Sports events

Note: ‘Other’ includes a wide range of different activities and settings, each of which has small numbers of individuals, as well as activities which did not fit any specific category and were added as ‘Other’ by the case. This includes: all within ‘activities’; Arts, entertainment or recreation; Civil service or government; Close contact services; Community and charity activities; Critical national infrastructure; Emergency services; Financial services; Food production; Hospitality; Immigration border services; Information and communication; Military; Personal care; Prison; Private events and celebrations; Public events and mass gathering; event within a shared household; Sport events; Supported living; Teaching and education; Transport; ‘Other (combined)’ includes all exposure group types that have small counts such as “went to church”, “went to the zoo” within that event type.

Delta variant outbreaks in schools increasing – we don’t know how many children are affected in each outbreak

Figure 10. Number of confirmed SARS-CoV-2 outbreaks or clusters in primary and secondary schools (including special educational needs settings) by variant type identified and epidemiological week, from 26 April to 30 May 2021
These data are provisional, excluding confirmed Alpha variant outbreaks.


Lateral Flow Device tests are not happening
Summary

Cases are going up in England and Scotland, and are flat or falling in Wales and Northern Ireland.

Vaccination going very well but disparities persist. Getting as many people protected by two doses as quickly as possible must remain the priority.

Cases are rising particularly in school age children.

We now have an exponentially increasing dominant variant that is more transmissible, more vaccine resistant and likely more severe than Alpha (B.1.1.7).

We need to get cases down now to protect children’s education, prevent many more cases of long covid, save lives and remove opportunities for this variant to mutate further.